Harvard Apparatus Regenerative Technology, Inc. (HRGN): Entry into a Material Definitive Agreement

Harvard Apparatus Regenerative Technology, Inc. (HRGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 11, 2026, Harvard Apparatus Regenerative Technology, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the I

Event · Offering · closed
Instrument
common stock
Gross proceeds
$2,838,911
Shares
2,703,727 shares
Price per share
$1.05

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 14, 2026, 2:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 2:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$HRGN
Bearish
medium confidence
Mentioned
$HRGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HRGNBearishLow
01

Why it matters

The filing discloses a $2.84 million private placement and note conversion by the CEO, providing fresh capital but increasing share count.

02

Market read

Primary disclosure of a small capital raise for a micro‑cap biotech; limited immediate market impact.

03

What to watch

CEO's note conversion reduces debt, strengthening balance sheet.

Relevance 6/10Novelty 6/10Timing: post‑market Sep 14

Background

SEC Form 8‑K filing reports Harvard Apparatus Regenerative Technology's entry into a securities purchase agreement and unregistered equity sale.

Company-level read

Ticker impact

$HRGNBearishMedium confidence
Context

Harvard Apparatus Regenerative Technology entered a private placement raising $2.84 million by selling 2.7 M shares at $1.05 each.

Expected impact

Slight downward pressure on the stock due to dilution.

Evidence & confidence

Small raise of $2.8 M in a low‑float micro‑cap is unlikely to move price dramatically, but dilution may cause modest sell‑off.

Market effects

Minimal effect on regenerative‑medicine sector; dilution modestly raises supply of shares.

Limited to US micro‑cap investors.

Low; primarily relevant to niche biotech investors.

Counterpoint

The cash infusion could fund R&D and improve long‑term growth, offsetting dilution concerns.

Key entities

  • Harvard Apparatus Regenerative Technology, Inc.

    Issuer of the private placement.

  • Jerry (Junli) He

    CEO who purchased shares and converted notes.

Related articles

$DJTMed

How Low Can Bitcoin Fall Before Trump Media Has to Sell?

Trump Media & Technology Group (DJT) may sell Bitcoin (BTC) to repay debt by November 30. With 9,542 BTC valued at $580M, a price drop increases the number of coins needed to meet obligations. Noteholders can demand $883.5M in cash, and DJT's stock is trading far below the conversion price of its notes.

$NEEMed

NextEra Energy Is Slowing Dividend Growth From 10% to 6%. Here’s Why

NextEra Energy (NEE) plans to reduce its dividend growth rate from 10% to 6% annually from 2026 through 2028. The company's earnings per share (EPS) are expected to grow at an 8%+ annual rate through 2035, providing a buffer for dividend increases. NextEra faces cash flow pressures due to heavy capital spending, but management expects operating cash flow to keep pace with EPS growth. The company's shares closed at $83.45 on November 20, with a forward dividend yield of 2.87%.

$MNTKMed

Tycoon Johnny Copelyn's Montauk warns of year-end default

Montauk Renewables Inc., chaired by Johnny Copelyn, warned of a potential default on loan covenants by Dec. 31, 2026, unless lenders agree to relief. The company's cash reserves halved this year, while long-term debt and accounts payable increased. Revenue rose 10.9% to $50.2 million, but net income fell 59% to $2.1 million. The company cut its 2026 revenue forecast due to lower prices for environmental attributes and operational issues at its Turkey, North Carolina facility.